R107
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.540
- ALLOGRAFT_REJECTION+0.520
- INFLAMMATORY_RESPONSE+0.470
- CHOLESTEROL_HOMEOSTASIS+0.420
- TNFA_SIGNALING_VIA_NFKB+0.420
- KRAS_SIGNALING_DN+0.360
- INTERFERON_GAMMA_RESPONSE+0.350
- MYOGENESIS+0.350
- COAGULATION+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
Top 10 suppressed
- PROTEIN_SECRETION-0.470
- FATTY_ACID_METABOLISM-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
- PEROXISOME-0.280
- MYC_TARGETS_V1-0.270
- MITOTIC_SPINDLE-0.250
- ANDROGEN_RESPONSE-0.240
- MYC_TARGETS_V2-0.230
- ADIPOGENESIS-0.200
- DNA_REPAIR-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1125 | Med | Medulloblastoma | 0.907 |
| 2 | X41226e40.d143.43b1.ac92.023809990077 | — | cohortA1 | 0.887 |
| 3 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.886 |
| 4 | TCGA-LD-A9QF-01A-32R-A41B-07 | — | D | 0.881 |
| 5 | BS_PJPGVD62 | Ependymoma NOS | — | 0.880 |
| 6 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.879 |
| 7 | BS_TA9WP4TH | Med | Medulloblastoma | 0.876 |
| 8 | R101 | — | — | 0.873 |
| 9 | SRR2778056 | — | — | 0.868 |
| 10 | 22f63ce0-5364-48b0-b424-5b971a1dcd33 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |